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Abstract
Introduction
The purpose of the present work was to determine if the use of biological-based objectives on
target volumes and critical structures in the optimizer could produce a superior plan when
compared to using only physical objectives for patients with intermediate-risk prostate cancer
with insertion of SpaceOAR Hydrogel.
Methods
Three planning techniques were created and compared retrospectively for 10 different radiation
therapy patients using Varian Eclipse treatment planning system utilizing volumetric modulated
arc therapy (VMAT) treatment planning. Each technique used different planning objectives
including dose volume (DV) objectives, target generalized equivalent uniform dose (gEUD)
objectives, and a combination of DV objectives with target and critical structure gEUDs. Doses
to target volumes and organs at risk were analyzed using dose volume histograms and dose
statistics for each plan.
Results
Based on dose volume histograms and dose statistics it was determined the utilization of
biological-based objectives produced improvements to plan quality. The target gEUD allowed
for decreased maximum dose and better fall off to the targets receiving 103% of the dose. The
target gEUD reported more conformal and homogeneous treatment plans. The addition of upper
gEUD objectives on the bladder and rectum resulted in significant improvements with reduction
in dose mainly to the volumes receiving 80 Gy or more.
Conclusion
For the cases in this study, the addition of biological-based objectives resulted in improved
maximum doses and critical structure dose sparing that is on par with, and mostly significantly
lower than physical-based planning objectives. Recommendations were provided for alpha
values and priorities for gEUD values on target volumes and critical structures.
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Introduction
Prostate cancer is the second most common type of cancer in American men, ranking
only behind skin cancer1. The American Cancer Society (ACS) estimates for prostate cancer in
the United States for 2020 are as follows: About 191,930 new cases and about 33,330 deaths will
result from prostate cancer1. During his lifetime, a man has a 1 in 9 chance of developing
prostate cancer1. Prostate cancer ranks as the second leading cause of cancer death in American
men, ranking behind lung cancer 1.
Most prostate cancers are commonly found during routine screening with a prostatespecific antigen (PSA) blood test or a digital rectal exam (DRE)2. A PSA blood test is often used
as a screening measure for men without symptoms, but it is also one of the first tests done if
symptoms present that are believed to be cancer2. If the results of any test are indicative of
cancer, a biopsy if often done to confirm2. Once prostate cancer is confirmed, it is assigned a
grade using the Gleason grading system. This system compares the biopsy to the appearance of
normal prostate tissue and assigns a grade based on abnormality from the normal appearance2.
Low-grade, or well-differentiated cancer is given a score of 6 or less2. Intermediate-grade, or
moderately-differentiated is given a score of 72. Poorly-differentiated or high-grade is given a
score of 8-102. When found in early to intermediate stages, prostate cancer is a treatable and
curable disease.
There are multiples approaches to treating prostate cancers. The most common options
include active surveillance, surgery, radiation, and hormonal therapy1. Active surveillance, or
watchful waiting, refers to monitoring cancer very closely instead of proceeding with treatment1.
This is often the case for older men or men who might be considered at risk due to other serious
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health issues1. Surgery for prostate cancer is a radical prostatectomy1. This is a common
approach when the cancer does not appear to have spread outside of the prostate gland1. A
radical prostatectomy removes the entire prostate gland and the seminal vesicles1.
Hormone therapy, also called androgen suppression therapy, is used to reduce levels of
male hormones, called androgens, in the body to stop them from fueling prostate cancer cells2.
Hormone therapy may be used if the cancer has spread too far to be cured by surgery or
radiation, if a patient cannot have these treatments due to other health complications, the cancer
remains or comes back after treatment with surgery or radiation therapy, in combination with
radiation if there is a high risk of the cancer coming back after treatment, or prior to radiation
aiming to shrink the cancer to make treatment more effective 2. Radiation therapy is the most
common treatment for low-grade cancers remaining in the intact prostate, cancers extending into
nearby tissues, cancer that has not been removed completely or comes back (recurs) in the area
of the prostate after surgery, or in advanced cases of disease2.
Radiation therapy plays a very important role in prostate cancer treatment. Radiation can
be delivered in the form of internal radiation, called brachytherapy, or external beam radiation
therapy (EBRT). Brachytherapy is most often used in early stage or in combination with EBRT
for higher risk patients. The two types of brachytherapy treatment options are permanent seed
implants and temporary, high dose rate therapy. Permanent seed implant brachytherapy (also
called seed implantation or interstitial radiation) refers to the insertion of very small, radioactive
pellets, often called seeds, directly into the prostate2.
EBRT uses high-energy beams, such as X-rays or protons, to kill cancer cells 3. EBRT
has greatly evolved over the years with aims at reducing risk to critical structures. The standard
of care was previously three-dimensional (3D-CRT) conformal radiation therapy which uses
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special imaging technologies to precisely map the location of the prostate and radiation beams
are then shaped and aimed at the prostate from several locations, thereby lessening the dose to
normal tissues2. 3D-CRT beams are stationary and are shaped by lead leaves called multi-leaf
collimators (MLCs) in the head of the traditional linear accelerator (LINAC) to conform to the
treatment volume.
Dose given to normal tissues surrounding the target (integral dose) and dose to organs at
risk (OARs) is what drove the advancement of 3D-CRT to intensity modulated radiation therapy
(IMRT), which is now the standard of care for prostate cancer treatment. IMRT refers to using
varying intensities of the photon beam at multiple angles to deliver dose safely and accurately to
the tumor cells4. The MLCs are able to move across the treatment field to vary dose and shape
the treatment field by blocking out critical structures4.
An advancement and subtype of IMRT is volumetric modulated arc therapy (VMAT).
Toeh et al5 describes VMAT as a novel radiation technique, which can achieve highly conformal
dose distributions with improved target volume coverage and sparing of normal tissues compared
with conventional radiotherapy techniques. The beam varies intensity as it rotates around the
patient consistently delivering dose, allowing less dose to be given to critical structures by
covering a larger area.
Due to these improvements in treatment techniques, very high doses can be delivered
with the goal to kill cancer cells, but extra caution must be taken when critical structures are near
the planning target volume (PTV). The prostate is located anterior to the rectum and inferior to
the bladder6. The small and large bowels are situated in the space superior to the prostate and can
sink down into the space surrounding the prostate7. The femurs are located laterally to the
prostate8. With the prostate located centrally to these critical structures and situated just anterior
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to the rectum, is it critical to use treatment techniques that spare these OARs while delivering the
dose prescribed to the volume.
With advancements in treatment to the prostate, patients are generally expected to live
long after their radiotherapy. For this reason, there are very specific constraints which must be
considered during the planning process to reduce toxicity to patients to ensure their quality of life
for years to come. Due to the close proximity of several OARs to the prostate, planning can
become challenging to meet constraints. The Quantitative Analyses of Normal Tissue Effects in
the Clinic (QUANTEC) suggests dose (Gy), or dose/volume parameters for conventional
fractionation to critical structures. For the rectum dose/volume parameters are as follows to avoid
late rectal toxicity: V50 < 50%, V60 < 35%, V65 < 25%, V70 < 20%, V75 < 15%9. For the
small bowel, individual bowel loops V15 < 120 cc to avoid acute toxicity9. To avoid late urinary
toxicity, the maximum dose (dmax) to the bladder must be kept < 65 Gy, V65 < 50%, V70 <
35%, V75 < 25%, V80 < 15%9. Potential side effects from EBRT include but are not limited to:
fatigue, rectal pain, bleeding, burning, and diarrhea, urinary incontinence, burning sensation
while urinating, and urethral stricture, erectile dysfunction2.
With the use of EBRT, the dose to normal tissues and OARs must be kept as low as
reasonably achievable (ALARA) while providing adequate coverage to the PTV. For prostate
patients, one improvement in treatment is the introduction of SpaceOar Hydrogel (SOH), a
temporary absorbable gel that is injected into the space between the rectum and prostate to
reduce dose to the rectum by creating additional space between the two, thereby reducing
potential side effects10. Whalley et al11 investigated the risks and benefits of SOH and
determined rectal doses to be significantly lower for patients with SOH versus patients without
SOH. Minimal post-insertion side-effects were reported, and late grade 1 gastrointestinal toxicity
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was significantly less in the SOH group (16.6% versus 41.8%). Whalley et al11 reported
significantly lower rectal doses for SOH plans, especially doses above 65 Gy (V82 = 0.2%
versus 1.3%; V80 = 0.8% versus 5.3%; V75 = 2.2% versus 9.5%; V70 = 3.7% versus 12.3%;
V65 = 5.4% versus 14.7%; V40 = 22.9% versus 32% and V30 = 42.7% versus 49.4%).
VMAT also has many advantages and techniques to achieve dose constraints. Treatment
planning systems (TPS) allow the treatment planner to input upper and lower limits, called
objectives, to give the TPS restrictions and constraints it must meet to provide adequate coverage
while sparing OARs. Thus, VMAT can sculpt the dose around the PTV using inverse planning.
Inverse planning uses complex photon optimization (PO) algorithms to achieve these seemingly
conflicting goals.
Using dosimetric objectives in the optimization enables the planner to define limits which
affect the dose distribution, such as dose volume constraints, minimum or maximum dose,
treatment time or MU limits, and radiobiologic effects12. An optimization objective uses input
parameters that are dosimetric and geometric characteristics of each field 13. Each optimization
objective has an optimization priority and dose and volume goal (dosegoal, volumegoal)
represented by a 2-dimensional position on a dose volume histogram (DVH) graph, and an
objective weighting derived from P, (objectiveweight (P)) using a heuristic power-law formula 13,14.
Using these objectives in the optimization, the planners can tell the system goals they wish to
achieve for each volume, and it will consider those objectives to create a plan. A plan is then
evaluated using a dose volume histogram (DVH). The DVH is a graphical representation of the
distribution of dose within a structure 15.
With advancements being made to the PO and its usefulness gaining popularity, Varian
Eclipse TPS Version 13.5 and newer has recently introduced the use of a biologically based PO
7

algorithm called generalized equivalent uniform dose (gEUD), an extension of the Equivalent
Uniform Dose (EUD) concept, developed by Niemierko. The biological effects of an applied
dose can be accounted for by using biological objective functions with IMRT16. EUD is specified
for tumor only, but gEUD can be used for both tumor volume and the OARs16. For tumors, the
EUD represents the biologically equivalent dose which, if given uniformly, leads to the same cell
kill in the tumor volume as the actual non-uniform IMRT dose-distribution17. QUANTEC
defines gEUD as, “The dose that, if given uniformly to the entire organ, is believed to yield the
same complication rate as the true dose distribution”18. With updated versions of Varian TPS, the
PO enables users to combine the gEUD objective as well as a variety of most general dosevolume (DV) objectives in the same optimization19. Using these tools in combination could help
achieve treatment goals, but little research has been done on using gEUD on a target structure.
Fogliata et al19 explains the gEUD: “The gEUD is associated with the parameter a that
accounts for the seriality of a structure, being higher for more serial organs.” In a tutorial for
using gEUD, Bullock20 further explains: Parameter a is a tissue specific parameter that defines
on which part of the DVH curve the optimization focuses upon. It is negative for all tumors and
positive for all OARs20. Using an a value of 1 is the equivalent of using a mean objective20.
Parallel structures (lung, kidney, parotids, etc.) are associated with lower a values and focus on
mean dose and affect the majority of the DVH curve20. Higher a values are used with serial
structures (spinal cord, brainstem, optic chiasm, etc.) and focus on the maximum dose (Dmax) of
the DVH curve20.
Many studies have shown promising results with the implementation of gEUD in the PO
over the years. In 2007, Mihailidis et al21 compared plans for 10 individual intact breast and
chest wall patients using optimized IMRT plans with gEUD‐based objectives for OARs and then
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compared the results to plans using physical DV constraints19. The plan evaluation for the
gEUD-based plan resulted in greater OAR sparing while maintaining coverage for the target
volume. The V20 of the ipsilateral lung saw a reduction in dose on the gEUD-based plan from
22% to 18% 21. Moving forward to 2011, Dirscherl et al16 compared the DVHs of the physical
optimized plan and the ‘best’ plan of the ‘pseudo’ Pareto gEUD-based plan, and concluded the
V70 in the bladder decreased from 45.6% in the PO to 29.4% in the biological optimization
(BO), the rectum decreased from 31.4% to 25%, but the target homogeneity was better for the
PO plan.
In 2012, Dogan22 compared 10 head and neck (H&N) VMAT plans using Pinnacle3
Smart Arc TPS. This study assessed dose to the critical structures cord, parotids, brainstem, and
esophagus. Dogan concluded superiority in critical structure sparing in the gEUD-based plans
yielding up to a 55% reduction in cord D2 (dose to 2% of the volume), 35% reduction in Dmean
to the parotids, and 14% reduction in D2 of the brainstem. This study resulted in significant
sparing to the critical structures using gEUD-based planning, while maintaining a somewhat
similar target coverage in comparison to the DV-based plan22.
In 2014, T-F Lee, et al 23 compared and evaluated the difference between 10 DV-based
plans to DV-gEUD optimized plans for bilateral breast cancer (BBC). This study analyzed the
V20 Gy and V30 Gy of the heart and lungs, mean dose, and the normal tissue complication
probability. The authors concluded both plans met the requirements for coverage, but the DVgEUD plan was advantageous in dose sparing for OAR: mean doses of the lung V20 Gy, and
heart V30 Gy, in the DV-gEUD plan were lower than those in the DV plan23.
More recently, studies have become more involved by studying the gEUD specific a
parameter. In 2017, Fogliata et al19 studied the gEUD optimization for OAR in the PO of Eclipse
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treatment planning system using a cylindrical phantom with a target and OAR present and placed
at different distances and/or cropped from the target. The study aimed to assess the specific a
parameter of the gEUD by varying the parameter from 0.1-40 and studying the impact of the
parameter on the target and OAR. The authors concluded gEUD to be a powerful tool, allowing
dose sparing to the OAR while maintaining coverage to the PTV.
Most publications agree gEUD-based planning is superior to DV-based planning in
providing dose sparing to critical structures, but very few have studied the impact of using gEUD
on the planning target volume. In 2017, Apinorasethkul et al.17 studied several different body
sites using gEUD optimization and DV-based planning and summarized in agreement with other
studies stating gEUD generally shows greater OAR sparing. This study also suggests more
research needs to be done on the use of gEUD on target volumes in the future.
The main purpose of this study aims to determine if gEUD-based optimization can be
useful on target volumes in VMAT treatment planning for intermediate risk prostate treatment.
The study intends to examine the dosimetric impact of gEUD on the PTV in combination with
OARs and determine if this could be a useful tool in sparing OARs while improving target
volume.
Null hypothesis (Ho): Using gEUD on the PTV and OAR structures in the optimizer will
not provide better tumor coverage and lower critical structure doses for prostate patients with
SOH.
Alternative hypothesis (Ha): Using gEUD on the PTV and OAR structures in the optimizer
will provide better tumor coverage and lower critical structure doses for prostate patients with
SOH.
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Methods and Materials
Patient Selection
This is a retrospective study of 10 male patients previously treated for intermediate risk
prostate cancer using VMAT technique. A list of patients was obtained and reviewed for
selecting patients who met the research criterion. The patients were deidentified in the Varian
Eclipse TPS. The deidentified patients were then replanned by the same planner, using the same
beam configurations, same prescriptions, and the same treatment volumes as defined by the same
physician.
IRB
After the researcher completed the required CITI courses through Grand Valley State
University (GVSU), the Internal Review Board (IRB) approval process was initiated. A research
proposal was written and submitted to the clinic’s administration along with the details for
handling Protected Health Information (PHI). This agreement included the researcher’s plan to
protect the deidentified patient data by complying with the Health Insurance Portability and
Accountability Act 1996 (HIPPA). The plan included protecting data on a password protected
computer only accessible by the researcher. A HIPPA agreement was signed, and the research
project was approved through the clinic and submitted to GVSU’s IRB board. The research
project was approved through the GVSU IRB under the exempt review status.
Simulation
Each patient was consulted by the same Radiation Oncologist. After consultation, the
patients were scheduled for gold marker and SpaceOAR hydrogel placement. One week after
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these procedures were performed the patients were simulated in treatment position using the GE
CT simulator. The patients were also scanned using the GE MRI on the same day for the purpose
of visualization of the SpaceOAR for delineation of the structure by the physician. Patients were
scanned lying in the headfirst supine position with a pillow for the head, table pad under the
back, and a vac lock underneath the legs for immobilization and reproducibility of daily setup by
the therapists. All patients kept their arms folded across their chest. Each patient was instructed
to arrive with a full bladder and empty rectum for simulation and treatment. This was evaluated
to meet physician preferences before releasing the patients. The patients were marked with a
three-point setup on each patient’s skin at the anterior and lateral levels for correct positioning.
Planning
After simulation, the contouring and planning process was initiated. All plans were
created using Varian Eclipse TPS version 15.6 using the Varian True Beam treatment machine
and Anisotropic Analytical Algorithms (AAA) for calculations. For the purposes of this study,
each plan was created by the same planner to keep the integrity the same for each plan. To
maintain consistency, the same Radiation Oncologist delineated the target volumes, and all
OARs were reviewed or contoured by the researcher. The contoured structures included the
bladder, body, bowel, left and right femoral heads, gold markers, penile bulb, prostate, PTV 45
Gy and PTV 79.2 Gy, rectum, seminal vesicles, skin, and SpaceOar. Subtracted structures were
created for the bladder and rectum by cropping both structures 3 mm out of the PTV. A control
ring was utilized to allow for better coverage and to push dose to the target by extracting an outer
wall from the PTV of 1.5 cm and an inner wall of -0.4 cm.
After all contouring and preplanning structures were completed, a plan was created using
6MV VMAT technique with 2 arcs of 190-170 degrees clockwise and counterclockwise with
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collimator angles on 10 and 350 degrees, respectively. All MLCs were fitted to the PTV 45 Gy
structure with a 1 mm margin and recommended fixed jaw positions were used. The beam
configurations remained consistent throughout the study. For research purposes and ease of
comparison, the larger target volume labeled PTV 45 Gy was the only PTV used and was taken
to the total prescription dose of 79.2 Gy and the sequential boost was not planned. For the
evaluation of all plans the DVH was used and QUANTEC recommendations were followed.
QUANTEC recommends for structure PTV the V79.2 Gy > 95%. Bladder constraints are as
follows: V65 < 50%, V70 < 35%, V75 < 25%, V80 < 15%. The rectum should be kept below the
following: V50 < 50%, V60 < 35%, V65 < 25%, V70 < 20%, V75 < 15%. For the femoral
heads, the maximum dose should be < 54 Gy.
A total of three plans were created for each patient. The first plan was created using a
typical planning approach of using dose-volume objectives (DVOs) in the optimizer (DV Plan);
the second plan was created by copying the initial DV Plan and adding gEUD constraints to the
PTV (Target gEUD) and the third plan (Target + OAR gEUD) was created by copying Target
gEUD and adding gEUD constraints to the bladder and rectum.
The DV Plan had upper and lower objectives for PTV and several upper objectives for
the OARs. The PTV upper objective was set for 0% of the volume to receive 105% of the Rx
dose and the lower objective was set for 100% of the volume to receive 7920 cGy. One upper
objective of 79.2 Gy to receive 0% of dose was added to the ring structure. An avoidance
structure was created to push dose away from the rectum and used for each optimization. The
same initial objectives were used for all DV Plans. For this research, the rectal and bladder dose
were studied. The initial upper objectives were set based on the actual dose and slowly dropped
as the DVH curve met constraints. After the first calculation, the plan was individually evaluated
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and further optimized to meet dose constraints. During optimization, the DVH curve was
analyzed, and changes made based on response. If the DVH lines were not responding as shown
visually and in the cost function, priorities were raised to see movement. The planner used a
scale of 1-100 for the priorities, and values above 100 were utilized when necessary. The 30 Gy
line was continuously evaluated during optimization to ensure close conformity of dose to the
target was met. The conformity of the dose was evaluated for the rectum and bladder only. As
seen in Figure 1, the aims were to keep the conformity within 1.2 cm from the posterior PTV
contour to the 30 Gy line extending into the rectum and within minimal limits into the bladder.
Each plan was run an average of 3-5 times until constraints and coverage were met and doses
kept to ALARA. All plans were normalized at 100% of dose covers 95% of target volume to
meet recommended constraints and reduce hot spots.
For Target + gEUD, the researcher copied the DV Plan and added gEUDs to the PTV
only. A target gEUD and a lower gEUD were added with alpha values of -1, and a priority value
of 75 (with a dose value of the prescription dose 7920 cGy). The alpha value of -1 mainly works
to achieve the minimum dose requested. Using the target and lower gEUD simultaneously, the
planner aimed to have a more homogenous dose distribution and keep the max dose down.
Although an upper gEUD with alpha value of 40 theoretically should control the max dose, the
researcher in preliminary testing did not see an improvement and therefore did not use for the
study. All other prior DVOs were kept the same and the prior plan was used as the intermediate
dose. Each plan was then run once and achieved similar results.
After using the target gEUD, the planner copied the Target + gEUD plan and created a
third plan (Target gEUD + OAR). The DV objectives were kept the same from the Target +
gEUD plan. The optimizer was restarted and in addition to the DV objectives on the subtracted
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structures, three upper gEUDs were added to the bladder and rectum whole structures. The
priorities were initially set to 60 and then changed accordingly in aims to lower the dose to the
structures. Alpha values of 0.5, 8, and 40 were assigned to each gEUD. The dose values were
initially set approximately 200 cGy lower than the actual calculated dose except for the alpha 40,
which was only lowered 25-50 cGy at a time, as this value proved to be very powerful. As the
plan met the dose constraints, the doses were further dropped until coverage was sacrificed. The
planner also increased the priorities on the upper and lower objectives on the PTV by 50-100 to
maintain coverage and control hot spots while pushing on the bladder and rectum. The plan was
rerun 2-5 times until acceptable results were achieved.
Conformity indices (CI) were collected on all plans. CI is defined as the ratio of the
between a fraction of the tumor volume or reference volume to the volume covered with a certain
isodose line24. The planner used the CIs in Eclipse dose statistics for all plans. Homogeneity
indices (HI) were calculated for each plan using the following formula: HI = D2% - D98%/Dp x
10025. The HI formula is a tool used to check for uniformity in the target volume25. All critical
plan data was collected from the DVH evaluation and transferred to an excel spreadsheet for
evaluation and comparison purposes.
Data Analysis
For statistical analysis, Grand Valley State University’s Statistics Center used IBM SPSS
Statistics 24 software. Due to the testing of independent variables and groups, Repeated
Measures ANOVA tests were performed on all variables.

Results
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The main purpose of this study is to determine if using gEUD objectives in the optimizer
can produce a better plan than only using DV-based objectives. The main goal is to study the
dose effects on structures when placing gEUD objectives on target structures and OARs and
provide a better understanding of the usefulness of this tool. Three different variations of plans
were made to determine if there was a significant impact on plan quality from one technique over
another technique.
Prostate 7920 cGy - PTV
The minimum (min), maximum (max), and mean doses to the PTV as well as the CI, HI,
and 103% fall off were evaluated for all three plans as seen in Table 1. The PTV min dose did
not show a significant difference, p = 0.678. A difference was reported for the max dose p =
0.002. According to the Pairwise Comparisons, see Table 2, the PTV max dose showed
statistically significance differences between the DV Plan and Target + OAR gEUD, p = 0.038,
with a mean difference of 1.04%. Differences were found between the Target gEUD and Target
+ OAR gEUD plans, p = 0.009, with a mean difference of 0.94%. No significant differences
were reported between the DV Plan and Target gEUD, p = 1.000. The max dose mean variance
was 1.04% lower for the Target + OAR GEUD plan. For the PTV mean, Mauchly’s test
indicated a violation of the sphericity assumption χ2 (2) = 9.983, p = 0.007 so GreenhouseGeisser correction was used. Greenhouse-Geisser Epsilon ε < 0.75 (ε = 0.584), F (1.168, 10.509)
= 70.099, p < 0.001. A significant difference between the means was reported for all three plans,
p < 0.001. The PTV mean was closest to 100% for the Target + gEUD plan with a mean variance
of 0.92%.
The CIs, HIs, and 103% fall off was also evaluated for each plan. The CIs reported p <
0.001, so Pairwise Comparison was used to evaluate the differences. No significant difference
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was seen between DV Plan and Target gEUD, p = 0.733. A significant difference was reported
between DV Plan and Target + OAR gEUD, p = 0.001, and Target gEUD and Target + OAR
gEUD, p < 0.001. The CI means ranged from 0.99-1.01, with Target gEUD reported as 1.00. The
HIs reported significance, p = 0.001. Pairwise Comparisons showed a difference between the DV
Plan and Target gEUD, p = 0.006 with a mean variance of 0.01. PTV 103% fall off was
evaluated and Mauchly’s test indicated a violation of the sphericity assumption χ2 (2) = 17.887,
p < 0.001 so Greenhouse-Geisser correction was used. Greenhouse-Geisser Epsilon ε < 0.75 (ε =
0.528), F (1.056, 9.508) = 58.065, p < 0.001. A significant difference was reported for the 103%
fall off for all three plans, p < 0.001. See Figure 2. The 103% fall off was lowest at 15.4% for the
Target gEUD plan, and highest for the DV Plan at 43.8%, with a mean variance of 28.4%.
Femoral heads
The left and right femoral heads were evaluated for max dose and did not prove to be
significantly different between any of the three plans, p = 0.473 and p = 0.126, respectively. See
Table 3.
Bowel
The max dose to the bowel was evaluated for all three plans and did not prove to be
significant between the three plans, p = 0.613. See Table 4.
Bladder
The bladder V30, V50, V70, V75, and V80 was evaluated as well as the max and mean
doses for all three plans. See Table 5. The values showing statistically significant results were
the bladder V80 (see Figure 3) and the max bladder dose. The bladder V80 was assessed and
Mauchly’s test indicated a violation of the sphericity assumption χ2 (2) = 10.079, p = 0.006 so
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Greenhouse-Geisser correction was used. Greenhouse-Geisser Epsilon ε < 0.75 (ε = 0.583), F
(1.165, 10.488) = 102.227, p < 0.001. Pairwise Comparisons reported a significance difference
between the DV Plan and Target + OAR gEUD as well as the Target gEUD and Target + OAR
gEUD, both resulting in p < 0.001. The lowest V80 was reported for the Target + OAR gEUD at
2.0%. The highest V80 was reported for the DV plan at 3.3%. There was no significant different
between the DV Plan and Target gEUD, p = 0.157.
The max bladder dose was found to be statistically significant, p = 0.002 so the Pairwise
Comparisons were assessed and found a significant difference occurred between the Target
gEUD and the Target + OAR gEUD, p = 0.008. The Target + OAR gEUD reported the least dose
to the bladder with a mean difference of 109.0 cGy. There were no significant differences
between plans for the mean bladder, p = 0.089. Overall, the Target + OAR gEUD reported to
lowest doses to all measures of the bladder.
Rectum
The rectum V30, V50, V70, V75, and V80 was evaluated as well as the max and mean
doses for all three plans. All results reported to be statistically significant, summarized in Table
6. According to the Pairwise Comparisons, the V30 and V50 differed between the DV Plan and
Target + OAR gEUD, p = 0.005 and 0.007, respectively. The V30 mean difference between the
plans was reported as 2.89% and the V50 mean difference was 0.95%. The Target + OAR gEUD
reported the lowest doses between the plans. The V70 differed between the DV Plan and Target
gEUD, p = 0.012 with a mean difference of 0.27% as well as the Target gEUD and Target +
OAR gEUD plans, p = 0.007 with a mean difference of 0.58%. The V75 showed differences
between the DV Plan and Target gEUD, p = 0.013 with a difference of 0.32%, as well as the
Target gEUD and the Target + OAR gEUD, p = 0.009 with a mean difference of 0.55%. The
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V80 reported significant differences between all three plans with a mean variance of 0.58%. See
Table 7.
The max dose to the rectum was evaluated and showed significant results, p < 0.001.
According to the Pairwise Comparisons, significance was seen between the DV Plan and Target
+ OAR gEUD, p = 0.002 with a mean difference of 196.91 cGy, and the Target gEUD and
Target + OAR gEUD, p < 0.001 with a mean difference of 291.67 cGy. There was no
significance reported between DV Plan and Target gEUD, p = 0.769.
The mean dose to the rectum was evaluated and showed significant results, p < 0.001.
The Pairwise Comparisons reported significant differences between all the plans. The mean
difference was 46.5 cGy between the DV Plan and Target gEUD, p = 0.047. The mean difference
was 158.77 cGy between Target gEUD and the Target + OAR gEUD, p = 0.001. The mean
difference was 205.27 cGy between the DV Plan and the Target + OAR gEUD, p < 0.001. The
Target + OAR gEUD reported the lowest doses to rectum for all measures.
This study found statistically significant differences between plans for all the PTV
volumes except for the min dose. This study also found statistically significant differences
between the bladder V80, max bladder, and between all volumes of the rectum. No statistically
important differences were found for the femoral heads max dose, bowel max dose or bladder
V30, V50, V70, V75 and mean bladder. It should be noted for the purposes of this study, no
gEUDs were added to the femurs or bowel for any of the plans.

Discussion
The purpose of this study is to analyze three different treatment planning techniques used
when treating intermediate risk prostate patients with SpaceOAR. The three planning techniques
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focus on using different objectives in the optimizer, namely the addition of gEUDs to the PTVs
and OARs in additional to typical DV objectives in aims to improve dose coverage and reduce
normal tissue complications. The dosimetric effects to the PTV and OARs were evaluated for
each plan. For this study, the PTV coverage volumes and the dose to the bladder and rectum
were the areas the researcher focused on improving. The researcher hypothesized the addition of
gEUD objectives to the PTV and the OARs would produce improvement to plan quality. All
volumes were analyzed statistically. Overall, improvements were seen with the addition of
gEUD objectives.
In efforts to study the effects of gEUD objectives, the researcher used one typical case of
prostate cancer to investigate the effects of physical and biological objectives. To answer the
question if one technique produces a better-quality plan, several things must be considered.
Namely, the available resources and experience planning DV-based objectives far exceeds that
of the gEUD-based planning for the planner. The planner’s previous version of Eclipse did not
support the gEUD function and only recently did an upgrade to Eclipse become available to the
planner to support the use of gEUD. Also, there is plenty of information available on DV-based
planning with experienced dosimetrists using this planning technique. When researching gEUD
planning, little information and resources are available and finding experienced gEUD planners
is limited.
When plan comparisons are done and planning time is considered, DV plans are quicker
based on experience. With the addition of target gEUDs, the positive and negative effects
become apparent, and hot and cold spots must be adjusted for, adding additional planning time.
The target gEUD increased the hot spot in the plan. This behavior was expected as seen in
previous research16. The addition of the lower gEUD to the target helped cool the plan back
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down. The researcher assumes with practice, the planning times would be similar between plans.
One limitation to comparison between plans in this study is not adding additional upper DV
objectives to the DV Plan for hot spot reduction. This could introduce error for comparison and
could result in a cooler plan similar to gEUD plans, also seen with the 103% fall off.
For conformality and homogeneity, the target gEUD produced the overall best results.
The statistical tests did not differ much between the gEUD plans as expected, and the researcher
concludes the addition of target gEUDs prove to be a useful tool for conformality and
homogeneity. The planner recognizes for the Target gEUD plan, no other constraints were
pushed on, and this could allow for the optimizer to only focus on the PTV coverage. This could
introduce the importance of timing for when to add the additional target constraints. These
important findings and significant results help to fill the gap in literature on the study of target
gEUDs.
In general, researchers agree compared with DV-based planning, gEUD-based planning
in combination with DV-based planning allows for better protection of critical structures16,17,23.
The current research agrees. Trial and error are involved with the use of gEUD and alpha values
to find what works for each individualized plan. Although lower alpha values used in this study
for the bladder and rectum work well for the gEUD plans, the researcher suspects this is partly
due to the DV-based objectives pushing on the high dose regions on the DVH curve. The lower
alpha values have a stronger influence on the low-medium dose regions of the DVH curve, and
the upper DV objectives are influencing the higher dose regions of the DVH curve. Therefore,
the researcher entertains the idea that higher alpha values could impact the curves for the bladder
and rectum in a similar way if the plan were run without DV objectives. This could make it more
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difficult to see the difference in plan comparisons if one wants to see strictly DV-based planning
versus gEUD-based planning.
There are several limitations to this study. First, all plans involve a combination of DVbased planning and gEUD-based planning. Second, when adding the gEUD to the critical
structures, the planner added gEUDs to the whole structures of the bladder and rectum after
pushing on subtracted structures in the original DV Plan. This could introduce confusion in
results. Furthermore, the lack of experience using gEUD also serves as a limitation to the study.
Further research needs to be conducted on a plan using only gEUD-based objectives in
the optimizer on the critical structures. More research could be conducted on alpha values and
priority combinations. Additional research is still needed on target gEUDs to see if similar
results to this study are obtained to help continue to fill the gap in research.

Conclusion
This study shows the use of gEUD-based optimization can be a powerful tool;
specifically, the addition of the target gEUD. Although acceptable PTV coverage, conformality,
homogeneity, and critical structure sparing can be obtained with all three plans, there was
significant 103% dose fall seen resulting from the addition of target gEUD objectives. The OAR
sparing was most noticeable around the 80 Gy line on the DVH curve. The use of target and
upper gEUD objectives seem to produce the best overall plan quality. This study agrees with
other data, using both DV and gEUD objectives produces a higher quality plan. The study also
concludes the addition of the target gEUD proves to be a useful tool for treatment planning.
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Appendix

Figure 1. Conformality of rectum and bladder.

Table 1. Dose statistics for PTV variables.

Measure

Plan
DVPLAN

PTV Min (%)

TARGET
GEUD
TARGET+OAR
GEUD

PTV CI

PTV 103%
Fall Off

87.95

DVPLAN

0.99

TARGET
GEUD
TARGET+OAR
GEUD
DVPLAN

PTV HI

87.53

TARGET
GEUD
TARGET+OAR
GEUD

TARGET
GEUD
TARGET+OAR
GEUD
DVPLAN

PTV Mean
(%)

87.48

108.2
2
108.1
2
107.1
8
102.6
4
101.7
2
101.9
6

DVPLAN

PTV Max
(%)

Mean,
Std

TARGET
GEUD
TARGET+OAR
GEUD

1.00
1.01
0.06
0.05
0.06

DVPLAN

43.28

TARGET
GEUD

15.42

TARGET+OAR
GEUD

20.57

4.1
3
3.4
8
3.3
4
1.1
9
1.1
7
0.9
5
0.3
9
0.2
8
0.2
4
0.0
1
0.0
2
0.0
2
0.0
1
0.0
1
0.0
1
14.
61
6.1
1

Mauchly's, df, pvalue)

Correction

F, df, p-value

2.99

2

0.22

Sphericity Assumed

0.4
0

2,18

0.68

1.98

2

0.37

Sphericity Assumed

8.6
0

2,18

0.00

9.98

2

0.01

Greenhouse-Geisser (0.584)

76.
10

1.168,10
.509

<0.0
01

3.88

2

0.14

Sphericity Assumed

22.
30

2,18

<0.0
01

3.68

2

0.16

Sphericity Assumed

11.
34

2,18

0.00

17.89

2

<0.001

Greenhouse-Geisser (0.528)

58.
07

1.056,9.
508

<0.0
01

7.2
8
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Table 2. Pairwise comparisons for PTV max variables.

Plan
DV plan

Target + OAR
gEUD

Target gEUD

Plan
Comparison
Target + OAR
gEUD
Target gEUD

Mean
Difference

Std.
Error

Sig. (p
value)

95% Confidence Interval
Lower
Upper
Bound
Bound

0.1
1.04

0.251
0.335

1
0.038

-0.637
0.58

0.837
2.022

DV plan
Target gEUD

-0.1
0.94

0.251
0.233

1
0.009

-0.837
0.255

0.637
1.625

DV plan
Target + OAR
gEUD

-1.04

0.335

0.038

-2.022

-0.058

-0.94

0.233

0.009

-1.625

-0.255

Figure 2. 103% Fall Off between DV Plan, Target gEUD and Target + OAR gEUD plans.

PTV 45 Gy was taken to the full dose of 79.2 Gy for all plans for the purpose of this study.
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Table 3. Dose statistics for left and right femoral heads.
Measure

FemL_Max (cGy)

FemR_Max (cGy)

Plan

Mean, Std

DVPLAN

4529.84

576.83

TARGET GEUD

4598.02

555.49

TARGET+OAR GEUD

4624.41

604.69

DVPLAN

4479.14

813.48

TARGET GEUD

4603.03

748.64

TARGET+OAR GEUD

4654.21

753.11

Mauchly's, df, p-value

Correction

F, df, p-value

0.29

2

0.87

Sphericity Assumed

0.78

2,18

0.47

1.74

2

0.42

Sphericity Assumed

2.33

2,18

0.13

Correction

F, df, p-value

Table 4. Dose statistics for max bowel variables.
Measure

Max Bowel (cGy)

Plan

Mean, Std

DVPLAN

3415.25

2357.73

TARGET GEUD

3295.03

2376.37

TARGET+OAR GEUD

3355.61

2537.86

Mauchly's, df, p-value)

5.03
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2

0.08

Sphericity Assumed

0.50

2,18

0.61

Table 5. Dose statistics for bladder variables.
Measure

Bladder_V30
(%)
Bladder_V50
(%)
Bladder_V70
(%)
Bladder_V75
(%)
Bladder_V80
(%)

Plan
DVPLAN

22.01

9.63

TARGET GEUD

22.13

10.2
2

TARGET+OAR
GEUD

21.92

9.48

DVPLAN

11.77

5.76

TARGET GEUD

11.82

5.72

TARGET+OAR
GEUD

11.79

5.86

DVPLAN

6.63

3.60

TARGET GEUD

6.71

3.67

TARGET+OAR
GEUD

6.59

3.78

DVPLAN

5.31

3.03

TARGET GEUD

5.45

3.15

TARGET+OAR
GEUD

5.28

3.22

DVPLAN

3.31

2.19

TARGET GEUD

3.21

2.19

TARGET+OAR
GEUD

1.98

1.94

8463.
17
8496.
68
8387.
67
1868.
85
1859.
76
1822.
70

125.
59
139.
26
97.4
9
653.
50
663.
91
625.
37

DVPLAN

Max Bladder
(cGy)

TARGET GEUD
TARGET+OAR
GEUD
DVPLAN

Mean Bladder
(cGy)

Mean,
Std

TARGET GEUD
TARGET+OAR
GEUD

Mauchly's, df, pvalue

Correction

F, df, p-value

1.73

2

0.42

Sphericity Assumed

0.13

2,18

0.88

5.20

2

0.07

Sphericity Assumed

0.05

2,18

0.95

12.74

2

0.00

Greenhouse-Geisser
(0.557)

1.21

1.113,10.
019

0.30

8.24

2

0.02

Greenhouse-Geisser
(0.609)

3.03

1.217,10.
956

0.11

10.08

2

0.01

Greenhouse-Geisser
(0.583)

102.
23

1.165,10.
488

<0.0
01

3.03

2

0.22

Sphericity Assumed

9.37

2,18

0.00

4.91

2

0.09

Sphericity Assumed

2.78

2,18

0.09
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Figure 3. Bladder V80 comparisons between DV Plan, Target gEUD, and Target + OAR gEUD

Table 6. Dose statistics for rectal variables.
Measure
Rectum_V30
(%)
Rectum_V50
(%)
Rectum_V70
(%)
Rectum_V75
(%)
Rectum_V80
(%)

Plan
DVPLAN

26.87

10.26

TARGET GEUD

25.60

9.68

TARGET+OAR
GEUD

23.98

8.73

DVPLAN

11.89

5.45

TARGET GEUD

11.52

5.28

TARGET+OAR
GEUD

10.94

5.26

DVPLAN

3.81

2.56

TARGET GEUD

4.08

2.69

TARGET+OAR
GEUD

3.50

2.54

DVPLAN

2.17

1.74

TARGET GEUD

2.49

1.92

TARGET+OAR
GEUD

1.94

1.68

DVPLAN

0.54

0.59

TARGET GEUD

0.74

0.75

TARGET+OAR
GEUD
DVPLAN

Max Rectum
(cGy)

TARGET GEUD
TARGET+OAR
GEUD
DVPLAN

Mean Rectum
(cGy)

Mean,
Std

TARGET GEUD
TARGET+OAR
GEUD

0.16

0.21

8211.
35
8234.
11
8014.
44
2423.
84
2377.
34
2218.
57

188.7
3
226.3
3
281.3
4
570.6
9
562.1
3
545.1
5

Mauchly's, df, pvalue)

Correction

0.81

2

0.67

Sphericity Assumed

12.3
4

2,18

<0.00
1

2.34

2

0.31

Sphericity Assumed

10.6
0

2,18

0.001

4.31

2

0.12

Sphericity Assumed

12.1
8

2,18

<0.00
1

2.49

2

0.29

Sphericity Assumed

11.9
2

2,18

0.001

17.32

2

<0.001

Greenhouse-Geisser
(0.000)

10.1
5

1.061,9.5
48

0.01

4.72

2

0.09

Sphericity Assumed

30.3
2

2,18

<0.00
1

3.67

2

0.16

Sphericity Assumed

37.9
8

2,18

<0.00
1
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F, df, p-value

Table 7. Pairwise comparisons for rectal volumes.

Plan
DV plan

Target + OAR
gEUD

Target gEUD

95% Confidence Interval
Upper
Lower Bound
Bound

Mean
Difference

Std.
Error

Sig. (p
value)

-0.201
0.381

0.06
0.128

0.025
0.047

-0.377
0.004

-0.026
0.757

DV plan
Target gEUD

0.201
0.582

0.06
0.178

0.025
0.029

0.026
0.061

0.377
1.104

DV plan
Target + OAR
gEUD

-0.381

0.128

0.047

-0.757

-0.004

-0.582

0.178

0.029

-1.104

-0.061

Plan Comparison
Target + OAR
gEUD
Target gEUD

Figure 3. Dose objectives for the PTV volumes.

Figure 4. Dose objectives for PTV volumes.
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